title: Single High-Dose Oral Vitamin D3 Therapy (Stoss): A Solution to Vitamin D Deficiency in Children With Inflammatory Bowel Disease?
abstract: OBJECTIVE
  Vitamin D deficiency is common in children with inflammatory bowel disease (IBD). The aim of this study was to determine the safety and efficacy of stoss therapy on vitamin D levels during a period of 6 months in children with IBD and vitamin D deficiency (<50 nmol/L).
  
  
  METHODS
  A retrospective chart review was undertaken, focusing upon children managed in the IBD clinic at Sydney Children's Hospital between 2006 and 2010. Those with a 25-hydroxyvitamin D (25-OHD) level <50 nmol/L and those who received stoss therapy were included in this study.
  
  
  RESULTS
  A total of 76 children received stoss therapy. There was a significant and sustained increase in 25-OHD levels at all of the time points compared with baseline (40.8 ± 7.5 nmol/L), 1 month (145.6 ± 51.8 nmol/L), 3 months (87.1 ± 28.4 nmol/L), and 6 months 69.2 ± 31.3 nmol/L). There were no significant changes in serum calcium, phosphate, or parathyroid hormone at any time points.
  
  
  CONCLUSIONS
  Stoss therapy safely and effectively achieved and maintained a level of 25-OHD >50 nmol/L during 6 months in these children with IBD. Further prospective studies are now required to confirm this finding and establish whether this intervention has other benefits.
authors.affiliation: *Department of Gastroenterology, Sydney Children's Hospital †School of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia ‡Department of Pediatrics, University of Otago (Christchurch), Christchurch, New Zealand §Department of Endocrinology, Sydney Children's Hospital, Sydney, New South Wales, Australia ||Department of Paediatric Gastroenterology, Shaare Zedek Medical Center, Jerusalem, Israel.
authors.forename: Darren
authors.initials: D
authors.lastname: Shepherd
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Day
authors.forename: Steven T
authors.initials: ST
authors.lastname: Leach
authors.forename: Robert
authors.initials: R
authors.lastname: Lopez
authors.forename: Rachel
authors.initials: R
authors.lastname: Messenger
authors.forename: Helen J
authors.initials: HJ
authors.lastname: Woodhead
authors.forename: Oren
authors.initials: O
authors.lastname: Ledder
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Lemberg
mesh_terms: D000293:Adolescent; D002112:Calcifediol / Q000097:blood* / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D002762:Cholecalciferol / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D015331:Cohort Studies; D003093:Colitis, Ulcerative / Q000503:physiopathology; D003424:Crohn Disease / Q000503:physiopathology; D019587:Dietary Supplements / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006776:Hospitals, Pediatric; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000503:physiopathology*; D008297:Male; D008499:Medical Records; D009517:New South Wales; D010044:Outpatient Clinics, Hospital; D012189:Retrospective Studies; D014808:Vitamin D Deficiency / Q000150:complications / Q000178:diet therapy* / Q000209:etiology / Q000378:metabolism
chemical_list: D002762:Cholecalciferol; D002112:Calcifediol